Center-Authored Papers

Filters: Keyword is PROSTATECTOMY  [Clear All Filters]
F
FitzGerald LM, Karlins E, Karyadi DM, Kwon EM, Koopmeiners JS, Stanford JL, Ostrander EA.  2009.  Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis.. Prostate cancer and prostatic diseases. 12(2):192-7. Abstract
Fitzgerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME et al..  2008.  Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.. BMC cancer. 8:230. Abstract
Flaig TW, Tangen CM, Hussain MHA, Stadler WM, Raghavan D, Crawford DE, Glodé ML.  2008.  Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(9):1532-6. Abstract
H
Huang Y, Isharwal S, Haese A, Chun FKH, Makarov DV, Feng Z, Han M, Humphreys E, Epstein JI, Partin AW et al..  2011.  Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.. BJU international. 107(10):1562-9. Abstract
L
Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery E, Barry MJ.  2008.  Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up.. Journal of general internal medicine. 23(11):1809-14. Abstract
M
Moinpour CM, Hayden KA, Unger JM, Thompson IM, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S et al..  2008.  Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(1):112-20. Abstract
P
Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL et al..  2009.  Evaluation of the 8q24 prostate cancer risk locus and MYC expression.. Cancer research. 69(13):5568-74. Abstract
R
Ramsey SD, Zeliadt SB, Fedorenko CR, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fairweather ME, Thompson IM et al..  2011.  Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions.. World journal of urology. 29(1):3-9. Abstract
Redman MW, Tangen CM, Goodman PJ, Lucia SM, Coltman CA, Thompson IM.  2008.  Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.. Cancer prevention research (Philadelphia, Pa.). 1(3):174-81. Abstract
Resnick MJ, Koyama T, Fan K-H, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM et al..  2013.  Long-term functional outcomes after treatment for localized prostate cancer.. The New England journal of medicine. 368(5):436-45. Abstract
S
Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, Lin DW.  2008.  Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.. The Journal of urology. 179(5):1775-9. Abstract
Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford DE.  2008.  The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794.. The Journal of urology. 180(6):2453-7;discussion2458. Abstract
T
Thompson IM, Tangen CM.  2012.  Prostate cancer--uncertainty and a way forward.. The New England journal of medicine. 367(3):270-1.
Thompson IM, Tangen CM, Paradelo J, Lucia SM, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G et al..  2009.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.. The Journal of urology. 181(3):956-62. Abstract
W
Wolf AMD, Wender RC, Etzioni R, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K et al..  2010.  American Cancer Society guideline for the early detection of prostate cancer: update 2010.. CA: a cancer journal for clinicians. 60(2):70-98. Abstract
Wright JL, Dalkin BL, True LD, Ellis WJ, Stanford JL, Lange PH, Lin DW.  2010.  Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality.. The Journal of urology. 183(6):2213-8. Abstract
Y
Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni R, Higano CS.  2010.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(16):2668-73. Abstract